Trial Profile

Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ebselen (Primary)
Indications Hearing loss; Tinnitus
Focus Adverse reactions
Sponsors Sound Pharmaceuticals

Most Recent Events

03 Jun 2026 Planned End Date changed from 23 Sep 2019 to NULL.
03 Jun 2026 Planned initiation date changed from 15 Jan 2018 to 1 Jun 2026.
03 Jun 2026 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com